Tarsus begins phase 2 trial of oral Lyme disease prevention drug

March 31, 2026 8:30 AM

Tarsus Pharmaceuticals (NASDAQ: TARS) announced it has dosed the first participant in a phase 2 clinical trial evaluating TP-05, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found